To Fight Cancer, Scientists Customize Cellular Proteins With Remarkable Precision
Scientists at the University of Massachusetts Amherst have developed two powerful new ways to precisely control proteins on the surface of living cells, a breakthrough that could significantly improve how cancer is treated and potentially transform therapies for many other diseases as well. The research focuses on customizing cellular proteins—either by destroying those that cause harm or by repairing and replacing them with fully functional versions.
This work comes from an interdisciplinary team led by Sankaran “Thai” Thayumanavan, a Distinguished Professor of chemistry and biomedical engineering at UMass Amherst. Their findings were published as both a full article and a Communication in the Journal of the American Chemical Society (JACS), underscoring the importance and novelty of the discovery.
At its core, the research addresses a long-standing challenge in protein-based therapies: how to selectively target the right protein, on the right cell, at the right time—without disrupting healthy cellular processes.
Why Cell-Surface Proteins Matter So Much
Cells are often pictured as simple spheres filled with internal machinery like the nucleus, mitochondria, and ribosomes. In reality, the cell membrane is one of the most critical and complex parts of the cell. It is densely covered with proteins that protrude outward, acting as sensors, messengers, and gatekeepers between the cell and its environment.
When these membrane proteins work properly, they help regulate growth, immune signaling, and communication with other cells. But when they become damaged or defective, the consequences can be severe. Some faulty proteins can instruct a cell to divide uncontrollably, a hallmark of cancer. Others can act as molecular disguises, helping cancer cells hide from the immune system.
Although only about 25% of the body’s 20,000-plus proteins are found on the cell membrane, nearly half of all existing drugs target these proteins. This makes them one of the most valuable—and challenging—targets in modern medicine.
A New Direction in Cancer Therapy
Many advanced cancer therapies already focus on targeting problematic membrane proteins. However, most rely on biochemical signals to remove or inhibit these proteins. The UMass Amherst team took a different approach by leveraging physical forces at the cell surface itself.
Instead of only using chemical cues, the researchers explored whether mechanically manipulating the cell membrane could activate the cell’s own internal disposal systems. This idea led to the development of a novel platform called PolyTAC, short for polymeric lysosome-targeting chimera.
How PolyTAC “Shreds” Cancer-Causing Proteins
The PolyTAC strategy is designed to identify and destroy specific disease-causing proteins on the cell surface. The system has two main components:
- A targeted antibody that recognizes a unique biomarker on the harmful protein
- A polymer that physically presses into the cell membrane
Once the antibody binds to the target protein, the polymer creates a small indent or dimple in the membrane at that exact location. This physical deformation is not accidental—it triggers the cell’s internalization machinery.
The cell interprets the dimple as a signal to pull that section of the membrane inward. The targeted protein is then routed into the cell’s lysosomal waste system, where it is broken down and destroyed.
Rather than hijacking existing receptors or chemical pathways, PolyTAC works by exploiting the cell’s natural response to mechanical stress. This makes it fundamentally different from earlier protein degradation technologies.
Researchers involved in the study describe the cell surface as being like a lawn full of weeds. The PolyTAC approach doesn’t damage the whole lawn—it identifies one specific weed and sends it directly to the shredder.
Beyond Destruction: Reprogramming Cells With ACDVs
While PolyTAC focuses on eliminating bad proteins, the second platform developed by the team takes a more constructive approach. This method is built around Artificial Cell-Derived Vesicles, or ACDVs.
Instead of destroying defective proteins, ACDVs allow scientists to add fully functional proteins directly to the cell surface, effectively reprogramming how the cell behaves.
ACDVs are vesicle-based systems that can fuse with a cell’s membrane and insert new proteins in real time. This opens the door to repairing cellular functions rather than simply removing what is broken.
Using this platform, the researchers successfully implanted four different functional proteins into cell membranes. These proteins were able to alter how the cells interacted with their environment, including how they signal to the immune system and how they regulate growth.
Why Protein Replacement Is a Big Deal
Most current therapies attempt to correct disease by targeting damaged proteins that already exist in the cell. The ACDV approach sidesteps this challenge by introducing healthy, fully functional proteins instead.
This has several major advantages:
- Cells can be reprogrammed rather than suppressed
- Therapies can be customized for individual patients
- Cancer cells can be forced to remove immune-evasion mechanisms
- Abnormal cell division can be actively corrected
Because the platform is flexible, researchers believe it could be adapted to deliver many therapeutic proteins already approved for clinical use, potentially accelerating real-world applications.
Platform Technologies With Broad Potential
One of the most important aspects of this research is that both PolyTAC and ACDV are described as platform technologies. This means they are not limited to one specific disease or protein.
Although cancer is the primary focus, the same strategies could be applied to a wide range of immunological and cellular disorders, including autoimmune diseases and conditions caused by dysfunctional cell signaling.
By either removing harmful proteins or replacing them with functional ones, scientists gain unprecedented control over how cells behave at their surface, where many diseases originate.
How This Fits Into the Bigger Scientific Picture
The UMass Amherst work builds on the growing field of targeted protein degradation, which includes well-known technologies like PROTACs and LYTACs. However, PolyTAC stands out because it does not rely on biochemical tagging or receptor hijacking.
Instead, it uses mechanical cues—a surprisingly elegant solution to a problem that has challenged scientists for decades.
Together, PolyTACs and ACDVs represent a shift toward precision engineering of cellular surfaces, allowing researchers to fine-tune biological systems with far greater accuracy and fewer unintended effects.
Looking Ahead
The ability to custom-tailor the protein landscape of a cell could reshape how diseases are treated in the future. Rather than relying on broad-spectrum drugs, therapies could be designed to act with surgical precision, minimizing side effects while maximizing effectiveness.
As research continues, these technologies may move from the lab into clinical settings, offering new hope for patients whose diseases are driven by faulty cellular proteins.
Research Papers
Polymeric Lysosome-Targeting Chimeras (PolyTACs): Extracellular Targeted Protein Degradation without Co-Opting Lysosome-Targeting Receptors
https://doi.org/10.1021/jacs.5c17519
Incorporation of Functional Proteins on Cellular Surfaces via Artificial Cell-Derived Vesicles (ACDVs) for Plasma Membrane Reprogramming
https://doi.org/10.1021/jacs.5c17697
